Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Bladder Cancer
58%
Transitional Cell Carcinoma
51%
Castration Resistant Prostate Cancer
48%
Kidney Metastasis
45%
Renal Cell Carcinoma
42%
Pembrolizumab
36%
Gemcitabine
35%
Disease
33%
Prostate Cancer
30%
Adverse Event
30%
Anticarcinogen
28%
Prostate Specific Antigen
26%
Neoplasm
25%
Androgen Receptor
24%
Chemotherapy
24%
Nivolumab
24%
Progression Free Survival
24%
Cisplatin
23%
Survival Rate
21%
C Reactive Protein
21%
Hemodialysis
20%
Malignant Neoplasm
20%
Combination Therapy
19%
Recurrent Disease
18%
Enfortumab Vedotin
18%
Cancer Specific Survival
17%
Enzalutamide
14%
Abiraterone Acetate
13%
Immunotherapy
13%
Immune Checkpoint Inhibitor
12%
microRNA 145
12%
Cabazitaxel
12%
Muscle Invasive Bladder Cancer
12%
Ipilimumab
12%
Immunoglobulin
12%
Docetaxel
11%
Biological Marker
11%
Androgen
9%
Liver Metastasis
9%
Biochemical Recurrence
9%
Bladder Tumor
9%
Disease Exacerbation
9%
Recurrence Free Survival
8%
Abiraterone
7%
Survival Prediction
7%
Chemoradiation Therapy
7%
Retrospective Study
7%
Recurrence Risk
7%
Diseases
7%
Medicine and Dentistry
Overall Survival
78%
Transitional Cell Carcinoma
76%
Cystectomy
43%
Robot-Assisted Prostatectomy
43%
Pembrolizumab
42%
Prostate Cancer
40%
Clear Cell Renal Cell Carcinoma
31%
Partial Nephrectomy
30%
Enfortumab Vedotin
30%
Prognostic Factor
28%
Neoplasm
28%
Progression Free Survival
24%
Retrospective Study
24%
Kidney Metastasis
24%
Bladder Cancer
23%
Continence
23%
Cancer Specific Survival
20%
Gemcitabine
19%
Nephroureterectomy
18%
Nivolumab
18%
Recurrent Disease
17%
Multivariate Analysis
17%
Disease
16%
Cisplatin
15%
Recurrence Free Survival
15%
Urinary System
14%
Urinary Diversion
14%
Castration Resistant Prostate Cancer
14%
Neutrophil
14%
Body Mass Index
13%
Lymphocyte
13%
Progressive Disease
13%
Postoperative Ileus
12%
Programmed Death-Ligand 1
12%
Adjuvant Chemotherapy
12%
Immune-Related Adverse Events
12%
Retroperitoneal Lymph Node Dissection
12%
Neoadjuvant Chemotherapy
12%
Invasive Bladder Cancer
12%
Bladder
12%
High Risk Population
12%
Combination Therapy
12%
Bleeding
11%
Intraarterial Drug Administration
11%
Adverse Event
10%
Geriatrics
10%
Anticarcinogen
10%
Propensity Score Matching
9%
Urine Incontinence
9%
Nephrectomy
9%
Keyphrases
Overall Survival
25%
Pembrolizumab
24%
Metastatic Urothelial Carcinoma
18%
Robot-assisted Radical Prostatectomy
18%
Metastatic Renal Cell Carcinoma (mRCC)
12%
Nephroureterectomy
12%
Upper Tract Urothelial Carcinoma
12%
Prognostic Impact
12%
Neutrophillymphocyte Ratio
12%
CDDP
12%
Bladder-sparing
12%
Balloon-occluded Arterial Infusion
12%
Invasive Bladder Cancer
12%
Japanese Patients
12%
Pentafecta Outcomes
12%
Cystectomy
9%
Complete Response
9%
Nerve Sparing
8%
Partial Nephrectomy
8%
Locally Invasive
8%
Medical Colleges
7%
Osaka
7%
Clinical Response
7%
Urothelial Carcinoma
7%
Multi-institutional
7%
Bladder
7%
Oncological Outcomes
7%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
7%
Bicalutamide
7%
Objective Response Rate
7%
Microvascular Invasion
6%
Localized Prostate Cancer
6%
Prostate Carcinoma
6%
Prognostic Factors
6%
Median Overall Survival
6%
Software Analysis
6%
Aortic Fistula
6%
Ureteral Stenting
6%
Flow Obstruction
6%
Tensin Homolog
6%
Abdominal Aortic
6%
Tramadol
6%
Transrectal Ultrasound
6%
Leiomyosarcoma
6%
Scrotum
6%
Pathologic
6%
Innovative System
6%
Outlet Obstruction
6%
Ultrasound-guided Core Needle Biopsy
6%
Total Cell-free DNA
6%